PMID- 29499349
OWN - NLM
STAT- MEDLINE
DCOM- 20181002
LR  - 20181004
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 117
DP  - 2018 May 30
TI  - Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging 
      and targeted therapy of cancer.
PG  - 301-312
LID - S0928-0987(18)30104-0 [pii]
LID - 10.1016/j.ejps.2018.02.027 [doi]
AB  - The side effects of chemotherapeutics during the course of cancer treatment limit 
      their clinical outcomes. The most important mission of the modern cancer therapy 
      modalities is the delivery of anticancer drugs specifically to the target 
      cells/tissue in order to avoid/reduce any inadvertent non-specific impacts on the 
      healthy normal cells. Nanocarriers decorated with a designated targeting ligand 
      such as aptamers (Aps) and antibodies (Abs) are able to deliver cargo molecules 
      to the target cells/tissue without affecting other neighboring cells, resulting 
      in an improved treatment of cancer. For targeted therapy of cancer, different 
      ligands (e.g., protein, peptide, Abs, Aps and small molecules) have widely been 
      used in the development of different targeting drug delivery systems (DDSs). Of 
      these homing agents, nucleic acid Aps show unique targeting potential with high 
      binding affinity to a variety of biological targets (e.g., genes, peptides, 
      proteins, and even cells and organs). Aps have widely been used as the targeting 
      agent, in large part due to their unique 3D structure, simplicity in synthesis 
      and functionalization, high chemical flexibility, low immunogenicity and 
      toxicity, and cell/tissue penetration capability in some cases. Here, in this 
      review, we provide important insights on Ap-decorated multimodal nanosystems 
      (NSs) and discuss their applications in targeted therapy and imaging of cancer.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Vandghanooni, Somayeh
AU  - Vandghanooni S
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Eskandani, Morteza
AU  - Eskandani M
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Barar, Jaleh
AU  - Barar J
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz, Iran; Department of Pharmaceutics, 
      Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Omidi, Yadollah
AU  - Omidi Y
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz, Iran; Department of Pharmaceutics, 
      Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 
      Electronic address: yomidi@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180227
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Antibodies)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Aptamers, Nucleotide)
RN  - 0 (Drug Carriers)
RN  - 0 (Lipids)
RN  - 0 (Polymers)
SB  - IM
MH  - Animals
MH  - Antibodies/chemistry/metabolism
MH  - Antineoplastic Agents/*administration & dosage/adverse 
      effects/chemistry/metabolism
MH  - Aptamers, Nucleotide/chemistry/metabolism
MH  - *Drug Carriers
MH  - Drug Compounding
MH  - Humans
MH  - Lipids/chemistry
MH  - Molecular Imaging/*methods
MH  - *Nanoparticles
MH  - Neoplasms/*diagnostic imaging/*drug therapy/metabolism
MH  - Polymers/chemistry
MH  - Predictive Value of Tests
MH  - Technology, Pharmaceutical/*methods
MH  - *Theranostic Nanomedicine
OTO - NOTNLM
OT  - Aptamer
OT  - Cancer therapy
OT  - Drug delivery systems
OT  - Nanomedicine
OT  - Nanoparticles
OT  - Targeted therapy
OT  - Theranostics
EDAT- 2018/03/03 06:00
MHDA- 2018/10/03 06:00
CRDT- 2018/03/03 06:00
PHST- 2017/10/22 00:00 [received]
PHST- 2018/02/24 00:00 [revised]
PHST- 2018/02/25 00:00 [accepted]
PHST- 2018/03/03 06:00 [pubmed]
PHST- 2018/10/03 06:00 [medline]
PHST- 2018/03/03 06:00 [entrez]
AID - S0928-0987(18)30104-0 [pii]
AID - 10.1016/j.ejps.2018.02.027 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2018 May 30;117:301-312. doi: 10.1016/j.ejps.2018.02.027. Epub 
      2018 Feb 27.